T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120

Gene Therapy

Volumn 12, Issue 4, 2005, Pages 299-310

  Masiero, S ^a   Del Vecchio, C ^a   Gavioli, R ^b   Mattiuzzo, G ^a   Cusi, M G ^c   Micheli, L ^c   Gennari, F ^a   Siccardi, A ^d   Marasco, W A ^e   Palu G ^a   Parolin, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; CD8+ cell engineering; Chimeric TCR; HIV 1 envelope glycoprotein

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; CYTOKINE; GLYCOPROTEIN GP 120; INTERLEUKIN 2; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F105; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CELL STRAIN COS1; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE MEMBRANE; LYMPHOCYTE TRANSFER; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; T LYMPHOCYTE;

ANIMALS; ANTIBODY SPECIFICITY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; CHIMERA; COS CELLS; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 20044385229     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302413     Document Type: Article

References (62)

1. Borrow P et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
2. Koup RA et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
3. Borrow P et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-211.
4. Jin X et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-998.
5. Manca F et al. Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Gene Therapy 1997; 4: 1216-1224.
6. Manca F et al. Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro expanded CD4 lymphocytes. Immunol Lett 1999; 66: 117-120.
7. Palù G et al. Genetically modified immunocompetent cells in HIV infection. Gene Therapy 2001; 8: 1593-1600.
8. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single-chain consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
9. Altenschmidt U et al. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 1997; 75: 259-266.
10. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76.
11. Becker ML et al. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 1989; 58: 911-921.
12. Goverman J et al. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 1990; 60: 929-939.
13. Paillard F et al. Immunotherapy with T cells bearing chimeric antitumor receptors. Hum Gene Ther 1999; 10: 151-153.
14. Geiger TL, Leitenberg D, Flavell RA. The TCR-ζ chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. J Immunol 1999; 162: 5931-5939.
15. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991; 64: 1037-1046.
16. Brocker T, Peter A, Traunecker A, Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol 1993; 23: 1435-1439.
17. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997; 45: 131-136.
18. Annenkov A, Chernajovsky Y. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta. Gene Therapy 2000; 7: 714-722.
19. Roberts MR et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994; 84: 2878-2889.
20. Yang OO et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 1997; 94: 11478-11483.
21. Walker RE et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-474.
22. Deeks SG et al. A phase II randomized study of HIV-specific T cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5 788-797.
23. Mitsuyasu RT et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-793.
24. Posner MR et al. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991; 146: 4325-4332.
25. Thali M et al. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991; 65: 6188-6193.
26. Matsuda S, Mariguchi T, Coyasu S, Nishida E. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem 1998; 273: 12378-12382.
27. Whitehurst CE, Boulton TG, Cobb MH, Geppert TD. Extracellular signal-regulated kinases in T cells. Anti-CD3 and 4 beta-phorbol 12-myristate 13-acetate-induced phosphorylation and activation. J Immunol 1992; 148: 3230-3237.
28. Moore JP, Jarret RF. Sensitive ELISA for the gp120 and gp160 surface glycoprotein of HIV-1. AIDS Res Hum Retroviruses 1988; 4 369-379.
29. Oh SK et al. Identification of HIV-1 envelope glycoproteins in the serum of AIDS and ARC patients. J Acquir Immune Defic Syndr 1992; 5: 251-256.
30. Hildinger M, Abe KL, Ostertag W, Baum C. Design of 5′ untranslated sequences in retroviral vectors develop for medical use. J Virol 1999; 73: 4083-4089.
31. Schambach A et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
32. Engels B et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Human Gene Ther 2003; 14 1155-1168.
33. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
34. Miller AD et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
35. Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
36. Uckert W et al. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum Gene Ther 2000; 11: 1005-1014.
37. Riddel SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Ann Rev Immunol 1995; 13: 545-586.
38. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 2000; 45 (Suppl T3): 35-43.
39. Mangasarian A et al. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 1999; 73: 1964-1973.
40. Piguet VL et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000; 2: 163-167.
41. Whitehurst CE, Geppert TD. MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. J Immunol 1996; 156: 1020-1029.
42. Hege KM et al. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. J Exp Med 1996; 184: 2261-2269.
43. Yang OO et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 2002; 76: 1626-1631.
44. Bitton N, Verrier F, Debre P, Gorochov G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 1998; 28: 4177-4187.
45. Patel SD et al. Impact of chimeric immune receptor extracellular protein domain on T cell function. Gene Therapy 1999; 6: 412-419.
46. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991; 64: 891-901.
47. Maher et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nature Biotech 2002; 20: 70-75.
48. Bitton N, Gorochov G, Debre P, Eshhar Z. Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. Front Biosci 1999; 4: D386-D393; (review).
49. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989; 86 10024-10028.
50. Samino Y et al. An endogenous HIV envelope-derived peptide without the terminal NH3+ group anchor is physiologically presented by major histocompatibility complex class I molecules. J Biol Chem 2004; 279: 1151-1160.
51. Severino ME, Sarkis PTN, Walker BD, Yang OO. Chimerical immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology 2003; 306: 371-375.
52. Banerjee R et al. Productive nonlytic human immunodeficiency virus type 1 replication in a newly established human leukemia cell line. Proc Natl Acad Sci USA 1992; 89: 9996-10000.
53. Cullen BR. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol 1987; 152 684-704.
54. Potter H, Weir L, Leder P. Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci USA 1984; 81: 7161-7165.
55. Weissman AM et al. Molecular cloning of the zeta chain of the T cell antigen receptor. Science 1988; 239: 1018-1021.
56. Zomoyska R et al. Two Lyt-2 polypeptides arise from a single gene by alternative splicing patterns of mRNA. Cell 1985; 43: 153-163.
57. Marasco WA et al. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest 1992; 90: 1467-1478.
58. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993; 90: 7889-7893.
59. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
60. Fehse B et al. A novel 'sort suicide' fusion gene vector for T cell manipulation. Gene Therapy 2002; 9: 1633-1638.
61. Sodroski J et al. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986; 322: 470-474.
62. Jawetz E, Melnick JL, Adelberg EA. Serologic diagnosis and immunologic detection of virus infection. In: Jawetz E, Melnick JL, Adelberg EA (eds.) Review of Medical Microbiology. Lange Medical Publications: Los Altos, 1980, pp 371-385.